Reported about 16 hours ago
The FTC has released a report accusing the top three pharmacy benefit managers (PBMs) of inflating specialty drug prices by thousands of percent, leading to an estimated $7.3 billion in revenue from 2017 to 2022. The report highlights significant markups on lifesaving medications and calls for continued investigation into the practices of PBMs, which have been accused of contributing to rising healthcare costs. Despite these claims, the PBMs refute the allegations, asserting that they save patients money.
Source: YAHOO